派林生物(000403) - 2024 Q3 - 季度财报

Financial Performance - Revenue for the third quarter reached 754.09 million yuan, a year-on-year increase of 13.27%[3] - Net profit attributable to shareholders of the listed company was 215.75 million yuan, up 17.86% year-on-year[3] - Total revenue for the quarter reached 1,890,265,336.27 yuan, a significant increase from 1,374,813,312.16 yuan in the same period last year[16] - Net profit for the quarter was 542,758,460.07 yuan, up from 325,813,319.79 yuan in the previous year[17] - Operating profit increased to 638,752,175.75 yuan, compared to 372,635,563.90 yuan in the prior year[17] - Comprehensive income for the period totaled 542,752,820.16 yuan, an increase from 325,834,307.14 yuan in the previous period[18] - Basic and diluted earnings per share were 0.7425 yuan, up from 0.4460 yuan in the previous period[18] Assets and Liabilities - Total assets as of the end of the reporting period were 9.05 billion yuan, an increase of 4.90% compared to the end of the previous year[3] - Total assets grew to 9,053,216,302.97 yuan, up from 8,630,474,084.53 yuan at the end of the previous quarter[13][15] - Fixed assets increased by 45.70% to 1.37 billion yuan as construction projects reached the expected usable state[6] - Fixed assets increased to 1,373,956,195.97 yuan, compared to 942,994,319.65 yuan in the previous quarter[13] - Total liabilities stood at 1,228,389,449.24 yuan, slightly higher than 1,208,610,202.73 yuan in the previous quarter[14] - Equity attributable to the parent company's shareholders increased to 7,831,710,847.17 yuan, up from 7,428,649,258.06 yuan in the previous quarter[15] Cash Flow and Investments - The company's cash flow from investment activities decreased by 78.03% to -841.55 million yuan, mainly due to increased purchases of cash management products[7] - Investment income surged by 574.51% to 29.39 million yuan due to realised gains from cash management products[7] - Cash received from sales of goods and services was 1,868,361,377.74 yuan, compared to 1,573,400,641.94 yuan in the previous period[19] - Net cash flow from operating activities was 227,534,196.54 yuan, slightly higher than 225,733,198.18 yuan in the previous period[20] - Cash received from investments was 940,000,000.00 yuan, doubling from 470,000,000.00 yuan in the previous period[20] - Net cash flow from investing activities was -841,549,214.80 yuan, a decrease from -472,711,848.24 yuan in the previous period[20] - Net cash flow from financing activities was -60,650,552.66 yuan, compared to 28,452,153.67 yuan in the previous period[20] - Net increase in cash and cash equivalents was -674,688,890.07 yuan, a decrease from -218,461,879.92 yuan in the previous period[21] - Ending cash and cash equivalents balance was 753,590,120.03 yuan, down from 781,808,629.21 yuan in the previous period[21] Research and Development - R&D expenditure increased by 36.16% to 92.10 million yuan, driven by increased capitalised R&D spending[6] - Research and development expenses decreased to 45,975,375.17 yuan, down from 53,761,401.55 yuan in the same period last year[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 19,784[8] - The largest shareholder, GQC Shengbang Yinghao Investment Partnership, holds 20.97% of the shares, amounting to 153,752,812 shares[8] - The second-largest shareholder, Harbin Tongzhicheng Technology Development Co., Ltd., holds 10.97% of the shares, amounting to 80,381,128 shares[8] - The third-largest shareholder, Shenzhen Shipping Health Technology Co., Ltd., holds 4.46% of the shares, amounting to 32,694,301 shares[8] Financial Position - The company's monetary funds at the end of the period were 754,186,603.94 yuan, a decrease from 1,429,349,951.47 yuan at the beginning of the period[12] - The company's trading financial assets increased to 1,000,209,682.43 yuan from 423,337,138.12 yuan at the beginning of the period[12] - The company's accounts receivable decreased to 571,175,853.29 yuan from 583,578,747.20 yuan at the beginning of the period[12] - The company's inventory increased to 1,139,194,714.69 yuan from 909,374,530.76 yuan at the beginning of the period[12] - The total current assets at the end of the period were 3,542,327,499.32 yuan, slightly increased from 3,426,074,653.60 yuan at the beginning of the period[12] Loans and Subsidies - The company's long-term loans rose by 38.33% to 271.23 million yuan, driven by increased fixed asset loans for project construction[6] - Government subsidies received during the period decreased by 33.96% to 6.41 million yuan[6] Return on Equity - The company's weighted average return on equity (ROE) increased by 0.18 percentage points to 2.79%[3] Construction Projects - The company's investment in construction projects decreased to 463,311,557.62 yuan, down from 582,699,721.94 yuan in the previous quarter[13] Financial Expenses - The company's financial expenses showed a net benefit of -36,946,315.96 yuan, compared to -42,850,779.46 yuan in the same period last year[16]